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ABSTRACT 
Objective: Febuxostat, a xanthine oxidoreductase inhibitor, is a drug of choice for hyperuricemia and Gout. But it also suffers from drawbacks in 
terms of pharmacokinetic profile and toxicity. It is available as immediate release formulation in the market. The objective is to develop a modified 
release formulation of febuxostat that can serve the dual purpose of increasing the efficacy and decreasing the toxicity, thereby improving safety.  
Methods: Pharmacokinetic and pharmacodynamic data, including drug concentration profile, efficacy data and toxicity data have been reviewed 
thoroughly. Based on available data, target pharmacokinetic profile has been identified as about 50 % reduction in Cmax
Results: Based on dissolution data and Wagner-Nelson calculations, the plasma concentration profile has been predicted for the developed 
formulation. It reconfirms that developed formulation will achieve the desired objectives. Formulation stability has been established up to 6 months 
under accelerated conditions.  
 and improvement in plasma 
drug concentration above required level during 6-24 hour. Desired in-vitro dissolution profile has been selected, and formulation modification has 
been sought to achieve the desired profile. The formulation has been prepared with a partial dose in the form of immediate release (IR) and 
remaining dose as an extended release (ER). IR and ER formulations have been developed separately and combined to form Inlay tablets containing 
ER inner tablet surrounded by IR.  
Conclusion: The developed formulation is a potential candidate for filing to a regulatory agency with the advantage of higher efficacy and less 
toxicity, which will be beneficial to the patient population and has good commercial viability.  
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INTRODUCTION 
Febuxostat, chemically 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-
methylthiazole-5-carboxylic acid, is a potent, non-purine selective 
inhibitor of xanthine oxidoreductase. Febuxostat 40 and 80 mg once 
daily (QD) is approved in the United States and the United Kingdom 
for the chronic management of hyperuricemia in patients with gout 
[1, 2]. 
Gout is a disease that results from the deposition of urate crystals in 
synovial fluid and other tissues due to its saturation in blood. There 
are four clinical stages viz. asymptomatic hyperuricemia, acute 
gouty arthritis, inter-critical gout and chronic tophaceous gout [3]. 
Xanthine oxidoreductase enzyme can be present in two different 
isozymic forms [4]. In one form, the xanthine oxidoreductase 
enzyme is synthesized as xanthine dehydrogenase, exhibiting a very 
low reactivity with oxygen. However, under stress or disease 
conditions, such as ischemia-reperfusion injury and congestive heart 
failure, xanthine dehydrogenase can undergo the formation of intra-
molecular disulfide bonds or proteolytic cleavage, which converts 
the enzyme to the second form, xanthine oxidase. Xanthine oxidase 
exhibits high reactivity with oxygen. Hyperuricemia is also 
associated with a number of disease conditions, such as renal injury 
and hypertension [1]. 
Hyperuricemia is defined as plasma or serum urate concentration 
greater than 70 mg/l (>420 μ mol/l) and is present in approximately 
5% of the population in the world. Serum uric acid (sUA) is the 
primarily important risk factor for the development of gout. 
Sustained hyperuricemia is a risk factor for acute clinically 
progressive stages of gout-like gouty arthritis, tophaceous gout and 
uric acid nephrolithiasis. Most patients with hyperuricemia will 
never have an attack of gout and remain untreated. In the Normative 
Aging Study, the 5-year cumulative risk of gout development in 
subjects with sUA levels >70 mg/l or >100 mg/l was 0.6% and 
30.5%, respectively [5, 6]. The higher the sUA levels greater the 
likelihood of developing gout.  
The available treatment option is uricosuric agent, increasing uric 
acid excretion and xanthine oxidoreductase inhibitor (Allopurinol 
and Febuxostat), reducing the synthesis of uric acid. Allopurinol 
has been shown to prevent renal injury and hypertension 
associated with hyperuricemia by inhibiting xanthine 
oxidoreductase; thus reducing uric acid levels. In contrast, it has 
been found that the extent of protection against renal injury and 
hypertension in subjects suffering from hyperuricemia is lower in 
subjects treated with the uricosuric agent benziodarone. 
Benziodarone does not inhibit xanthine oxidoreductase activity, 
but instead reduces plasma uric acid levels by increasing the 
excretion of uric acid in the kidney [7, 8]. Therefore, there is an 
unmet need for new dosage forms that not only reduce uric acid 
levels in hyperuricemic subjects, but are also capable of 
maintaining a high level of (namely, at least 80%) inhibition of 
xanthine oxidoreductase activity in order to protect subjects 
receiving these dosage forms throughout their treatment regimen 
(i. e., Dosing interval, which is typically twenty-four h) against 
increasing concentrations of oxygen free radicals. 
Another treatment for hyperuricemia in patients with chronic gout 
is with the compound febuxostat, a non-purine inhibitor of xanthine 
oxidase [9, 10]. Febuxostat is marketed in various countries with 
different brand names as immediate release tablets. In the United 
States of America (USA), it is marketed by Takeda Pharmaceuticals 
as Uloric tablets 40 & 80 mg [11]. Extensive pharmacokinetic and 
pharmacodynamic data have established that maintaining a 
concentration of febuxostat in plasma over a prolonged period of 
time provides similar efficacy to treatment with high doses of the 
drug. Generally, these studies have shown that maintaining a 
febuxostat plasma concentration of 0.1 µg/ml is essential to provide 
95% or greater inhibition of xanthine oxidase.  
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Currently, the only commercially available formulations of 
febuxostat are immediate release tablets. Extended or delayed 
release formulations of febuxostat are not available. Therefore, a 
formulation of febuxostat that maintains the drug concentration 
above the critical concentration of 0.1 µg/ml for an extended period 
of time is expected to result in the higher efficacy of the drug, and 
would be a desirable treatment option for control of hyperuricemia, 
gout, and many other disease states. 
Similar inference can also be taken from the blood concentration 
data of Febuxostat in fasting and non-fasting (fed) condition against 
the clinical effect in both conditions [12].  As shown in table 1 and fig. 
1, in fed condition, there is a 49 % decrease in Maximum plasma 
concentration (Cmax
  
) level and about a 18 % reduction in Area under 
curve (AUC) level in comparison to fasting conditions. In clinical 
terms, there is a 7 % greater decrease in urate level in fed condition 
as compared to fasting conditions. Marginal improvement of a 
clinical effect can be seen in spite of the decrease in peak and total 
plasma exposure of Febuxostat. This is probably due to higher 
amount of drug availability in blood during 6 to 24 hour time period 
after dosing, which can be clearly seen in figure 1, log scale graphical 
representation.
Table 1: Pharmacokinetic and clinical data summary of febuxostat tablets 80 mg 
Fbuxostat tablets 80 mg 
 Condition Cmax AUC Mean serum urate level 
Day 1 Day 6 % change 
Fasting 3.256 9.211 5.110 2.606 -51.16 
Fed 1.800 7.675 5.255 2.235 -58.49 




Fig. 1: Plasma concentration profile of Febuxostat tablets 80 mg, (a): Normal scale Representation; (b): Log scale representation 
 
Innovator, Takeda had initially conducted trials on tablets with 
two different strengths 80 and 120 mg and applied to the United 
States Food and Drug Administration (USFDA) for marketing 
approval. Based on the data review, USFDA had requested the 
withdrawal of the tablet of the strength of 120 mg and instead 
recommended to add the lower strength of 40 mg. Although 120 
mg is the most effective strength, this decision was based on the 
toxicity data reported in the clinical studies conducted by Takeda 
[13]. Clinical data indicated that Febuxostat is more potent and 
effective than allopurinol, but treatment with Febuxostat is 
associated with higher rates of cardiovascular thromboembolic 
events, including death. A total of about 12 deaths had been 
reported along with additional non-fatal cardiac events during 
clinical studies. Febuxostat remains the second choice of drug for 
the treatment of hyperuricaemia in spite of it being more effective 
than allopurinol due to its toxicity. 
Based on this information available from the literature, it can be 
inferred that (a) Febuxostat is a better choice of drug for treatment 
of hyperuricemia, (b) maintaining the optimal blood concentration 
for a longer duration is more important than achieving higher Cmax
This scenario thus presents an opportunity for some modifications 
in the pharmacokinetic parameters of Febuxostat driven by 
formulation design to achieve greater efficacy and reduced toxicity 
leading to the enhanced safety of a therapy for the same dose. Based 
on the data studied, the target had been set to achieve the required 
pharmacokinetic profile of a Febuxostat modified release 
formulation with, about 50 % reduction in C
 
for effective therapy in case of febuxostat.  
max
Altering the pharmacokinetic parameters of a drug is possible 
through the modification of the formulation where formulation and 
not the drug govern the requirements. Various methods of 
modification of drug release have been reported in the literature for 
different kinds of Active Pharmaceutical Ingredient (API) and the 
requirement of the formulation [14, 15]. Generally, conventional 
controlled release formulation provides good control of the release 
of the drug, but lacks in the quick onset of action while conventional 
delayed release formulation provides only delay in onset and no 
control after the delay. The requirement in the present case is for 
the first booster dose for quick onset of action and then a 
maintenance dose in controlled release manner. A few approaches 
that can render such kind of release pattern includes Multilayer 
tablet [16], Compression coated tablet and a mixture of variable 
release profile pellets in a single capsule. The approach selected in 
the present study is a combination of immediate release (IR) and 
extended release (ER) formulation, allowing an initial blood 
concentration (Loading dose) and then maintaining it above the 
therapeutically effective concentration for a longer duration 
(maintenance dose).  
 and improvement in 
plasma drug concentration above required level during 6-24 hour 
time period after dosing. 
The inlay tablet formulation was proposed with an extended release 
inner tablet surrounded by an immediate release blend as the outer 
layer [7]. 
MATERIALS AND METHODS 
Materials 
Febuxostat, Microcrystalline cellulose PH 101 of Signet, Lactose 
Monohydrate of DEF international, Croscarmellose sodium (AC-DI-
SOL), Hydroxypropyl cellulose (Klucel LF), Colloidal silicon dioxide 
(Aerosil 200 Pharma), Magnesium stearate (Ligamed, Veg grade), 
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Hypromellose 100 cps, 4000 cps and 15000 cps of Colorcon, Povidone 
K-30 of ISP, Isopropyl alcohol of Merck, Iron oxide Yellow of Koel.  
The equipment used for the development includes Rapid mixture 
granulator, Fluid bed drier/Rapid drier, Mill, Stirrer, Blender, 
Compression machine, Moisture balance, Hardness tester, 
Disintegration apparatus, Vernier caliper and Friability tester. 
Preparation of Immediate releases blend/tablet 
Immediate release blend for the tablet was prepared by a wet 
granulation process. The ingredients, Febuxostat, Microcrystalline 
cellulose, Lactose and part quantity of croscarmellose sodium were 
dispensed accurately, sifted through appropriate sieves and mixed 
in rapid mixture granulator (RMG). Dry mix was granulated with a 
binder solution of hydroxyl propyl cellulose (Klucel) in water. 
Granules were dried in fluid bed drier/Rapid drier at 50 °C to 60 °C 
temperature till loss on drying (LOD) value of less than 2.0 % was 
achieved, as measured by a halogen moisture balance. 
The dried granules were milled through a 1.5 mm sieve in the mill 
and any retained granules were milled through a 1.0 mm sieve. 
Milled granules were blended with the remaining quantity of 
croscarmellose sodium and aerosil and then lubricated with 
magnesium stearate.  
Immediate release part was also separately compressed on 8 mm 
punch to evaluate the feasibility and study compression parameters. 
Table 2(a) describes various representative compositions of 
immediate release blend of the formulation.  
Preparation of extended release inner tablet 
Extended release portion of the formulation has been prepared by 
the wet granulation process using a non-aqueous solvent as it 
contains polymers which are difficult to be granulated with water. 
The ingredients, Febuxostat, Microcrystalline cellulose, colorant 
(iron oxide yellow) and hypromellose were weighed accurately and 
mixed thoroughly in rapid mixture granulator. Granulation was done 
with a solution of Povidone in isopropyl alcohol. Granules were 
dried in fluid bed drier/Rapid drier, at a temperature of 45 °C to 55 
°C to achieve the targeted loss on drying (LOD) of less than 2.0 % 
measured using a halogen moisture balance. 
The dried granules were milled through a 1.5 mm sieve in the mill 
and the retained granules were milled through a 1.0 mm sieve. 
Milled granules were lubricated with magnesium stearate to obtain 
the final blend, which was then compressed into tablets of 8 mm on 
the rotary compression machine. Table 2(b) describes various 
representative compositions of the extended release fraction of the 
formulation.
 
Table 2(a): Representative compositions of immediate release part 
S. No. Batch No. F002 F004 F005 F006 F007 F008 F009 
Ingredients mg/tablet 
1 Febuxostat 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
2 Microcrystalline cellulose 101 50.0 50.0 50.0 50.0 50.0 50.0 50.0 
3 Lactose monohydrate  92.0 95.0 89.0 95.0 89.0 91.0 91.0 
4 Croscarmellose sodium (ACDISOL) 4.0 4.0 4.0 4.0 4.0 4.0 4.0 
6 Hydroxypropyl cellulose (Klucel LF) 5.0 2.0 8.0 5.0 5.0 5.0 5.0 
7 Purified water qs qs qs qs qs qs qs 
8 Croscarmellose sodium (ACDISOL) 6.0 6.0 6.0 3.0 9.0 6.0 6.0 
9 Colloidal silicon dioxide (aerosil 200) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
10 Magnesium stearate 2.0 2.0 2.0 2.0 2.0 1.0 3.0 
Total 200.0 200.0 200.0 200.0 200.0 200.0 200.0 
 
Table 2(b): Representative composition of extended release part 
S. No. Batch No. F010 F011 F012 F013 F014 F015 
Ingredients mg/tablet 
1 Febuxostat 40.0 40.0 40.0 40.0 40.0 40.0 
2 Microcrystalline cellulose 101 101.0 101.0 101.0 101.0 101.0 101.0 
3 Hypromellose 100 cps  50.0 - - 25.0 20.0 30.0 
4 Hypromellose K4M - 50.0 - 25.0 30.0 20.0 
5 Hypromellose K15M - - 50.0 - - - 
6 Iron oxide yellow 1.0 1.0 1.0 1.0 1.0 1.0 
7 Povidone K30 6.0 6.0 6.0 6.0 6.0 6.0 
8 Isopropyl alcohol qs qs qs qs qs qs 
9 Magnesium stearate 2.0 2.0 2.0 2.0 2.0 2.0 
Total 200.0 200.0 200.0 200.0 200.0 200.0 
 
Preparation of Inlay tablet 
Immediate release blend and extended release tablets were then 
combined to form inlay tablets manually. Figure 2 shows the picture 
of inlay tablets. 
 
 
Fig. 2: Inlay tablets of febuxostat 
Evaluation of IR& ER granules 
The granules were characterized for physical properties like bulk & 
tapped density, the angle of repose, Carr’s index, Hausner ratio and 
sieve analysis. 
Physical evaluation of ER and inlay tablets 
Five tablets from each formulation were randomly selected and 
organoleptic properties such as color, description and shape were 
evaluated. Thickness and diameter were also measured using 
Vernier calipers. The prepared tablets were evaluated for hardness, 
friability and uniformity of weight. 
Chemical evaluation of IR, ER and inlay tablets 
Uniformity of dosage unit, Dissolution, Assay, Related substance 
(RS) and water content were measured. HPLC methods for Assay 
and RS were developed in-house. Water content was measured as 
per the standard method using Karl Fisher apparatus.  
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In-vitro dissolution study  
In-vitro dissolution studies are valuable and important tools to judge the 
quality, stability and consistency of dosage forms and are often used to 
predict in-vivo performance. Dissolution of the tablet was carried out 
using a paddle (USP dissolution type II apparatus) at 75 Rotation per 
minutes (RPM), 900 mL of Phosphate buffer pH 6.8 (OGD recommended 
dissolution method). Dissolution medium in a dissolution vessel was 
maintained at a temperature of 37±0.5°C. 5 ml of the sample was 
withdrawn at regular intervals and replaced with the same volume pre-
warmed fresh dissolution medium. The percentage drug release was 
plotted against time to determine the release profile. 
In-vivo prediction 
In-vivo data of an immediate release reference product (Uloric 80 mg) 
from USFDA were utilized to generate the plasma concentration profile. 
Various pharmacokinetic parameters like Cmax, AUC0-t, AUCα, absorption 
constant (Kabs), elimination constant (Keli), half-life (t1/2
It was assumed that 100 % of the drug is available for absorption within 
10 minutes since immediate release tablets were considered. Wagnor 
Nelson (WN) values for the developed modified formulation were 
calculated considering the percentage of drug available at each time 
point based on the results of the dissolution studies. These derived WN 
values were used to inversely predict the fraction of a dose absorbed. 
The plasma concentration of the final modified-release (MR) formulation 
has been derived from the prediction made using the derived WN values.  
) etc. were also 
calculated. % absorption and absorption curve were defined. Wagnor 
Nelson (WN) values for each time point were also derived [18]. 
Formulation with different proportions of IR and ER part (40:60, 
50:50, 60:40) and other formulations (where dissolution was faster 
and slower) were also treated similarly and the calculated plasma 
concentration were derived for all the selected formulations.  
Calculation of the pharmacokinetic parameters 
Table 3(a) and Table 3(b) show the plasma concentration data and 
other calculated Pharmacokinetic parameters for Febuxostat 
immediate release tablets. Figure 4 shows the plasma profile along 
with extrapolation for absorption and residuals.  
From the plasma profile, the natural logarithm (ln) has been 
obtained for the concentration values. Keli
Extrapolated values have been calculated using the following equation:  
Y = mX + C 
 is the Slope of the 
elimination curve (preferable slope of the last four or appropriate non-
zero concentrations). Intercept has also been obtained from the same. 




Since intercept is in ln format, the equation would be as follows:  
Y =  e(−mx+C) 
Where m= slope, X = time point and C = Intercept 
Subtraction of Plasma concentration from Extrapolated values yields 
the residual concentration plot, and Slope of ln(residual) is K





calculated using AUC at the last time point along with concentration 
at last time point and elimination constant. 
Sum AUC at time t =  [Conct + Conct−1] × 
(t)− (t − 1)
2
+ AUC at time (t − 1) 
Conct
Conc
 = Plasma concentration at time t 
t-1
C
 = Plasma concentration at the preceding time point (t-1) 
AUC infinite 
= Sum AUC at last time point +




Absolute half-life was calculated using absorption constant and time 
for maximum concentration has been derived from the following 
equation as well as the time at which the plasma maximum plasma 
concentration achieved (C
 is the Maximum concentration achieved in profile 
max










Wagnor-Nelson values and Percentage absorption were calculated 
for each time point using the following equation.  
WN =  
Plasma conc at time t + (Keli × AUC till time t)
AUCinf × Keli
× 100 
%Absorption = 100 −  100 × e(Kabs×Timet) 
Inverse Wagner-nelson and prediction of in-vivo profile  
The calculated WN values are based on the consideration that 100 % 
of the drug is available for absorption within about 10 minutes in an 
immediate release (IR) product. WN values were also calculated for 
modified developed formulation based on the dissolution of a 
different formulation.  
WN =
Drug release at time t × WN value for IR at time t
100
 
Different dissolution values were then converted into WN values. 
These WN values were then converted into Predicted Fraction of 
Dose absorbed (Fd). Calculated Plasma concentration (CPC) values 
were also derived with the following equation 






2 × (Fd t2 − Fd t1) × dose in μg
Vd F⁄� + Conc t1{2− [Keli(t2 − t1)]}





 = Calculated Plasma concentration at time t2 
2
Fd t
 = Fraction of dose absorbed at time t2 (current time point for 
which we are calculating plasma concentration. 
1
Conc t
 = Fraction of dose absorbed at the preceding time point 
1
Stability studies 





AUC ×  Keli
 
Stability studies at accelerated condition were performed for 6 
months for the finalized prototype formulation and found to meet 
the standards as per the current regulatory requirements.  
Excipient compatibility studies 
Excipient compatibility studies were also performed on binary mixtures 
with 1:1 ratio of API to each excipient and exposed to 40 °C/ 75% RH 
and 50 °C/ 80 % RH for 1 month and analyzed for the related substance. 
RESULTS  
Immediate release formulation and extended release formulation 
have been developed separately and both have been combined in 
one formulation to get the desired formulation. Formulation 
development has been carried out using the Quality-by-design 
concept [21] of risk assessment and mitigation.  
Immediate release portion of the formulation has been kept mostly 
similar to that of the marketed product of Takeda and dissolution 
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studies of the developed IR portion were also compared with the 
marketed formulation. A comparison of the two established the 
similarity between them. IR portion of the inlay tablet releases the 
drug within 10 minutes and dissolution is close to 100 % in the same 
duration in both marketed formulation as well as the developed IR 
formulation. Various trials have been conducted at different levels of 
binder, disintegrant, and lubricant. The IR formulation has been 
optimized based on process observations and dissolution profile. 
Representative composition is described in table 2(a). 
Hypromellose was selected as the polymer for the development of 
ER portion. Different viscosity grades (100 cps, 4000 cps and 15000 
cps) were used for the development. Formulation trials were 
executed using different grades of polymer as well as combinations 
of different grades at different levels and the optimum polymer 
concentration has been identified to get the desired dissolution 
profile. Representative composition is listed in table 2(b). 
The IR and ER portions were combined to form an Inlay tablet 
having outer immediate release granules and inner ER tablets. 
Dissolution studies have been performed for IR tablets, ER tablets, 
and Inlay tablets as well. Fig. 3 represents the data of dissolution 
profile achieved in different trials during the development and 
optimization studies. 
Based on the in-vivo pharmacokinetic profile of Febuxostat IR 
formulation given in Figure 4, pharmacokinetic parameters were 
calculated as shown in table 3(a) and table 3(b). These parameters 
were further utilized for the prediction of plasma profiles of 
developed formulation using Wagnor-Nelson equation [22]. Fig. 5 
represents the dissolution profile of different combinations of IR 
and ER formulation while Figure 6 shows the predicted in-vivo 







Fig. 3: Dissolution profiles of,(a): Representative IR formulations; (b): Representative ER formulation; (c): Inlay tablet in comparison with 
IR and ER formulations. n=6 
 
 
Fig. 4: Plasma profile of Febuxostat IR reference tablet 
 
Fig. 5: Dissolution profile for Inlay tablets with different 
proportions of IR and ER portions. n=6
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Table 3(a): Plasma concentration and plasma profile of reference product 
Time [C] μg/ml ln [C] Sum AUC Extrapolated Residuals ln(res) 
0.00 0.00 --  --  3.15 3.15 1.15 
0.25 0.03 -3.51 0.00 2.90 2.87 1.05 
0.50 1.68 0.52 0.22 2.66 0.98 -0.02 
1.00 2.13 0.76 1.17 2.25 0.12 -2.16 
1.50 1.98 0.68 2.20 1.89 -0.09 -- 
2.00 1.63 0.49 3.10 1.60 -0.03 -- 
3.00 1.32 0.28 4.58 1.14 -0.18 -- 
4.00 0.95 -0.05 5.71 0.81 -0.14 -- 
6.00 0.34 -1.08 7.00 0.41 0.07 -2.64 
8.00 0.19 -1.66 7.53 0.21 0.02 -3.98 
10.00 0.12 -2.12 7.84 0.11 -0.01 -- 
12.00 0.08 -2.53 8.04 0.05 -0.03 -- 
16.00 0.04 -3.22 8.28 0.01 -0.03 -- 
24.00 0.06 -2.81 8.68 0.00 -0.06 -- 
 
Table 3(b): Calculated pharmacokinetic parameters of reference product 
Parameter Value Parameter Value 
k 0.339 eli k 3.503 abs 
Intercept 1.148 C 2.130 max 
t 2.042 1/2 Abs t 0.198 1/2 








Febuxostat is a molecule which requires modification in the 
formulation to change the pattern of its bioavailability at the site of 
action. The targeted changes in the pharmacokinetic/dissolution 
profile have been decided based on the available pharmacokinetic 
data of reference immediate release tablets.  
It has been reported in the literature [23] that from 10 to 120 mg 
of dose it follows linear pharmacokinetics and so any changes in 
the dosage will be reflected linearly in the pharmacokinetic 
profile. Considering the pharmacokinetic profile of 80 mg dose in 
fasting and fed conditions, it can be inferred that plasma 
concentration of febuxostat above a certain level for the longer 
period of time is more critical rather than higher Cmax
The observed clinical and pharmacokinetic difference in fasting and 
fed conditions can also be correlated to pH dependent solubility of 
febuxostat. It has more solubility in pH above 6.2 and specifically 
above pH 6.8. In fed conditions, probably the availability of the drug 
to higher pH gets delayed by about 2 h. This may have reduced the 
C
. Also 80 mg 
is the strength which has been found more effective in treatment 
as compared to 40 mg. 
max
These observations resulted in keeping the target profile as, 40 to 60 
% portion of the formulation needs to release the drug quickly (IR 
part). This target would help to achieve the C
 and helped to increase the blood concentration to a level above 
the required concentration in 6-24 h’ time duration. In the proposed 
formulation similar delay has been achieved using modification of 
the formulation. 
max level above 1 μg/ml. 
The remaining 60 to 40 % of the drug in the form of Extended-
release, which would slowly make the complete drug available 
within the next 4-8 h with less than 10 % the drug being made 
available in the 1st
The conventional controlled release formulation as reported for 
many of the drugs [24, 25] has the ability to retard the release of 
drug from the formulation and can be useful for the drugs where the 
initial quick onset of action is not required [26, 27]. These types of 
formulation are worthwhile when control of the drug release is 
required from the initial stage. Similar controlled release 
formulation is also reported for Febuxostat [28] but that will lack 
the initial boost required to get the plasma concentration above the 
required level. In comparison, the developed formulation has almost 
50 % drug as immediate release, which will provide the initial surge 
to get C
 h.  
max above certain required level. In the conventional 
controlled release formulation, it is difficult to achieve the similar 
level of Cmax. Also, the time to achieve Cmax will get delayed (Tmax) in 
such conventional controlled release formulations. The Tmax for the 
developed formulation will be very much similar to immediate 
release marketed formulation, resulting in clinically significant 
blood levels being achieved in time duration similar to IR 
formulation. 
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This targeted profile would have two major advantages over the 
conventional immediate release tablet formulation and its 
pharmacokinetic profile. First, it would provide better effect as 
compared to immediate release tablet and secondly, there will be a 
significant reduction in the toxicity of the drug due to the minimal 
amount of drug being exposed to the body at any given time point. 
This would, in turn, improve both safety and efficacy of the drug 
molecule and make it more suitable for human use.  
Patent applications EP2582812 A0 and US 2011/0311620 describe 
a modified release formulation of Febuxostat incorporating both 
immediate and delayed release beads in a single pharmaceutical 
composition. Different beads with modification in release profile 
were prepared and mixed with immediate release beads. The 
reported formulation is more complex in terms of the formulation as 
well as process. Beads, because of the higher surface area, require 
more amount of polymer for release control as compared to tablets. 
Additionally, the process of preparation of the beads is also time-
consuming, variable and requires sophisticated equipment. 
Instead, the concept of combining IR & ER formulation in a single inlay 
tablet requires less effort and is more feasible and simple solution to 
address the need. Formulation of dual release system of combination 
of fast and slow release has been reported for other drugs using the 
concept of bilayer tablets [29] and inlay tablets [30, 31].  
Few other Patent applications [32] describe controlled release 
formulation and the osmotic controlled formulation of Febuxostat. 
Unfortunately, both these formulations are deficient of the quick 
initial release essential in case of Febuxostat.  
The developed formulation of Febuxostat is simple, but novel and 
has significant value in terms of market potential as well as patient 
safety. This has a clear advantage over other reported modified 
release formulations of Febuxostat.  
Fig. 5 shows the dissolution of different combinations (ratio) of IR & 
ER portion of the modified release formulation and Figure 6 shows 
the predicted in-vivo profile for the formulation based on the 
calculation along with the plasma concentration profile of 
immediate release reference product.  
Calculated plasma profiles show that the target of raising the plasma 
concentration after 6 h would be achieved. Plasma concentration 
remains above 0.25 μg/ml for more than 10 h and above 0.1 μg/ml 
for more than 12 h. Developed formulation has a partial quantity in 
the form of immediate release formulation which helps to achieve 
the initial boost to get the Cmax
Final formulation as inlay tablet was charged for stability studies at 
accelerated conditions. The formulation was found to be stable up to 6 
months with control in related substances as well as dissolution 
profile.  
 and remaining part in the form of 
extended release or slow release that helps to achieve the required 
plasma concentration over extended periods. The modified 
formulation will be successful in serving the dual purpose of 
improving the efficacy as well as the reduction of toxicity.  
Excipient compatibility studies have also been conducted with 
binary mixtures in ratio of 1:1 of API with each individual excipient. 
Data shows that the drug is compatible with all the excipients used. 
The physical appearance of the binary mixtures also remained 
unchanged during the exposure period. 
CONCLUSION 
Current study describes the preparation of a modified release 
formulation of Febuxostat to improve its efficacy and reduce toxicity 
and thereby improving safety as well. Modifications in the 
formulation were required to get the desired pharmacokinetic 
profile. Two different formulations, immediate release (IR) and 
extended release (ER) have been developed separately and 
combined to form inlay tablets. The proposed formulation will be 
advantageous over conventional immediate release tablets available 
in the market. The proposed formulation has been studied 
extensively and the pharmacokinetic data and in-vivo prediction 
show it to have better efficacy and safety profile.  
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